The Wood on Clinuvel
Tuesday, 08 July, 2008
Clinuvel Pharmaceuticals [ASX: CUV] has set in train its plan to add international expertise to its board, with the appointment of a new non-executive director.
Jack Wood was appointed to the position today. Wood currently sits on the board of two Canadian biotechnology companies, Engene and QLT.
He also has experience in the Australian pharmaceutical sector, including eight years serving in various executive positons at CSL from 1992-2000.
Clinuvel is seeking international expertise in anticipation of the commercialisation of its photoprotective drug afamelanotide (CUV1647).
Ultra-processed foods linked to poor health, premature death
Evidence suggests a dose-response relationship between ultra-processed food consumption and...
Shorter radiotherapy course proves safe for prostate cancer
A significantly shorter course of radiotherapy for localised prostate cancer is just as safe and...
5-in-1 meningococcal vaccine proves effective
A life-saving meningococcal vaccine covering all five common strains of the deadly disease could...
